Vaccine Adjuvants Market - Global Forecast To 2029
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年12月 |
| ページ数 | 389 |
| 図表数 | 540 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global vaccine adjuvants market is projected to surpass USD 0.96 billion in 2029 from USD 0.70 billion in 2024, with a significant CAGR of 6.5%.
世界のワクチンアジュバント市場は、2024年の7億米ドルから2029年には9億6000万米ドルを超え、6.5%という大幅なCAGRで成長すると予測されています。
Innovations in adjuvants, such as toll-like receptor agonists, emulsions, and saponin-based compounds, increased immunization programs in regions like Asia-Pacific, Latin America, and Africa, and rising demand for veterinary vaccines are some of the factors projecting growth of the vaccine adjuvants market.
“The emulsion-based adjuvants segment accounted for the highest share in 2023.”
On the basis of product, the vaccine adjuvant market is segmented into emulsion-based adjuvants, pathogen components, saponin-based adjuvants, particulate-based adjuvants and other products. Emulsion-based adjuvants accounted for the dominant share due to their effectiveness in enhancing immune responses and diversified applications in various vaccine types such as infectious diseases, cancer, and others. The pathogen components segment is likely to grow at a significant CAGR owing to advancements in vaccine technology and increased demand for more targeted, effective vaccines.
“ Organic adjuvant type dominated the market in 2023”
The adjuvant type segment is divided into organic and inorganic adjuvants. Organic adjuvants dominated the market in 2023. The factors attributable to their dominance are their versatility in various vaccine platforms (including mRNA and DNA vaccines) and their ability to enhance the immune response in both human and veterinary vaccines. Inorganic adjuvants are anticipated to grow at a significant CAGR owing to various factors such as safety profiles, efficacy, cost-effectiveness, and broad application across both human and veterinary vaccines.
“ Infectious diseases segment held dominant share”
On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and other diseases. The infectious diseases segment dominated the market owing to the increasing prevalence of infectious diseases, the rise in immunization programs across the globe, and the rise in research & development funding. The cancer segment is likely to grow at a significant CAGR owing to the increased adoption of TLR agonists, oil-in-water emulsions, and cytokines in cancer vaccine development and the shift towards personalized vaccines.
“North America: the largest share of the vaccine adjuvants market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the vaccine adjuvants market in 2023 and is estimated to continue dominance during the forecast period. The region’s dominance is driven by advanced healthcare infrastructure, strong research and development activities, and the rising prevalence of infectious diseases and cancer. Furthermore, strong research & development for novel vaccine adjuvants and the presence of key market players in the region are some of the major factors projecting the growth of the market in the region.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the vaccine adjuvants market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tire 1 – 45%, Tire 2 – 35%, andTire 3 – 20%
- By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
GSK Plc (UK), Seppic (France), Croda International Plc (UK), SPI Pharma (UK), Phibro Animal Health Corporation (US), Agenus Inc. (US), Dynavax Technologies Corporation (US)are some of the major players operating in the vaccine adjuvants market.
Research Coverage:
This research report categorizes the vaccine adjuvants market product (driven by advanced healthcare infrastructure, strong research and development initiatives, and high cancer prevalence), adjuvant type (organic and inorganic), disease tye (infectious diseases, cancer, and others), application (commercial & research), vaccine type (human and veterinary), route of administration ( intramuscular, subcutaneous and other route of administration) nd region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the vaccine adjuvants market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the vaccine adjuvants market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the vaccine adjuvants and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising demand for vaccines and expanding government immunization programs, technological advancements & development of novel adjuvants, increasing livestock production and rising incidence of animal diseases, increased investment in research & development, and higher number of vaccines under pipeline), restraints (cost implications of vaccine adjuvant development and side effects and toxicity of adjuvants), opportunities (personalized and combination vaccines, increased investment in R&D plant-based vaccines and growth in companion animals market) and Challenges (concerns regarding animal-sourced vaccine adjuvants ) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies in vaccine adjuvants manufacturing, research and development activities, and new product launches in the vaccine adjuvants market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the vaccine adjuvants market
- Competitive Assessment: GSK Plc (UK), Sepppic (France), Croda International Plc (UK), SPI Pharma (UK) among others in the market.
Table of Contents
1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 35
1.3.1 MARKETS COVERED & REGIONAL SCOPE 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 36
1.4 CURRENCY CONSIDERED 37
1.5 STAKEHOLDERS 37
1.6 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.1.1 SECONDARY DATA 40
2.1.2 PRIMARY DATA 40
2.2 MARKET ESTIMATION METHODOLOGY 42
2.2.1 MARKET ESTIMATION 42
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 44
2.2.3 TOP-DOWN APPROACH 44
2.3 MARKET GROWTH RATE PROJECTIONS 46
2.4 DATA TRIANGULATION 48
2.5 RESEARCH ASSUMPTIONS 49
2.6 RESEARCH LIMITATIONS 50
2.7 RISK ANALYSIS 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 56
4.1 VACCINE ADJUVANTS MARKET OVERVIEW 56
4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2023) 57
4.3 VACCINE ADJUVANTS MARKET SHARE, BY VACCINE TYPE, 2024 VS. 2029 58
4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Rising demand for vaccines and expanding government immunization programs 61
5.2.1.2 Technological advancements and development of novel adjuvants 62
5.2.1.3 Increasing livestock production and rising incidence of animal diseases 62
5.2.1.4 Increased investments in research & development and high number of vaccine adjuvants under pipeline 63
5.2.2 RESTRAINTS 63
5.2.2.1 Cost implications of vaccine adjuvant development 63
5.2.2.2 Side effects and toxicity of adjuvants 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Personalized and combination vaccines 64
5.2.3.2 Increased investments in R&D of plant-based vaccines 65
5.2.3.3 Growth in companion animals market 65
5.2.4 CHALLENGES 65
5.2.4.1 Concerns regarding animal-sourced vaccine adjuvants 65
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 66
5.4 PRICING ANALYSIS 66
5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022–2024 67
5.4.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2024 68
5.5 SUPPLY CHAIN ANALYSIS 69
5.6 VALUE CHAIN ANALYSIS 70
5.7 ECOSYSTEM ANALYSIS 72
5.7.1 VACCINE ADJUVANTS MARKET: RAW MATERIAL SUPPLIERS 73
5.7.2 VACCINE ADJUVANTS MARKET: PRODUCT MANUFACTURERS 73
5.7.3 VACCINE ADJUVANTS MARKET: END USERS 73
5.7.4 VACCINE ADJUVANTS MARKET: REGULATORY BODIES 74
5.8 TECHNOLOGY ANALYSIS 75
5.8.1 KEY TECHNOLOGIES 75
5.8.1.1 Toll-like receptor (TLR) agonists 75
5.8.1.2 Emulsion-based adjuvants 75
5.8.2 COMPLEMENTARY TECHNOLOGIES 76
5.8.2.1 Artificial intelligence (AI) and machine learning (ML) 76
5.8.3 ADJACENT TECHNOLOGIES 76
5.8.3.1 Nanotechnology in vaccine delivery 76
5.9 PATENT ANALYSIS 77
5.10 KEY CONFERENCES & EVENTS, 2024–2025 78
5.11 REGULATORY ANALYSIS 79
5.11.1 REGULATORY LANDSCAPE 79
5.11.1.1 North America 79
5.11.1.1.1 US 79
5.11.1.1.2 Canada 79
5.11.1.2 Europe 79
5.11.1.3 Asia Pacific 79
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.12 INVESTMENT & FUNDING SCENARIO 83
5.13 PORTER’S FIVE FORCES ANALYSIS 84
5.13.1 THREAT OF NEW ENTRANTS 85
5.13.2 THREAT OF SUBSTITUTES 85
5.13.3 BARGAINING POWER OF BUYERS 85
5.13.4 BARGAINING POWER OF SUPPLIERS 85
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 85
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 86
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 86
5.14.2 BUYING CRITERIA FOR END USERS 87
5.15 TRADE ANALYSIS 89
5.15.1 IMPORT DATA 89
5.15.2 EXPORT DATA 90
5.16 PIPELINE DATA FOR VACCINE ADJUVANTS 91
5.17 IMPACT OF AI/GENERATIVE AI ON VACCINE ADJUVANTS MARKET 92
6 VACCINE ADJUVANTS MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
6.2 EMULSION ADJUVANTS 95
6.2.1 EXTENSIVE USE OF EMULSION ADJUVANTS IN HUMAN VACCINES TO DRIVE GROWTH 95
6.3 PATHOGEN COMPONENTS 99
6.3.1 INCREASING NUMBER OF PROMINENT MARKET PLAYERS OFFERING BACTERIA-DERIVED ADJUVANTS TO DRIVE SEGMENTAL GROWTH 99
6.4 SAPONIN-BASED ADJUVANTS 103
6.4.1 INCREASING USE AND GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET GROWTH 103
6.5 PARTICULATE-BASED ADJUVANTS 107
6.5.1 GROWING POPULARITY OF MINERAL-BASED ADJUVANTS TO PROPEL MARKET 107
6.6 OTHER ADJUVANTS 111
7 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 116
7.1 INTRODUCTION 117
7.2 ORGANIC ADJUVANTS 117
7.2.1 GROWING DEMAND FOR VACCINES WITH HIGH EFFICACY TO BOOST MARKET 117
7.3 INORGANIC ADJUVANTS 121
7.3.1 INCREASING USE OF INORGANIC ADJUVANTS FOR VETERINARY VACCINE DEVELOPMENT TO SUPPORT MARKET GROWTH 121
8 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 126
8.1 INTRODUCTION 127
8.2 INTRAMUSCULAR 127
8.2.1 INTRAMUSCULAR ROUTE TO BE LARGEST AND FASTEST-GROWING MARKET SEGMENT DURING FORECAST PERIOD 127
8.3 SUBCUTANEOUS 131
8.3.1 WIDESPREAD USE OF SUBCUTANEOUS ROUTE OF ADMINISTRATION TO BOOST MARKET 131
8.4 OTHER ROUTES OF ADMINISTRATION 136
9 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 141
9.1 INTRODUCTION 142
9.2 INFECTIOUS DISEASES 142
9.2.1 INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 142
9.3 CANCER 147
9.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH 147
9.4 OTHER DISEASES 151
10 VACCINE ADJUVANTS MARKET, BY APPLICATION 156
10.1 INTRODUCTION 157
10.2 RESEARCH APPLICATIONS 157
10.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET 157
10.3 COMMERCIAL APPLICATIONS 161
10.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH 161
11 VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 166
11.1 INTRODUCTION 167
11.2 HUMAN VACCINES 167
11.2.1 INFECTIOUS DISEASES 171
11.2.1.1 Rising prevalence of infectious diseases to drive market growth 171
11.2.2 THERAPEUTIC 175
11.2.2.1 Rising investments in development of therapeutic vaccines to boost market 175
11.3 VETERINARY VACCINES 179
11.3.1 COMPANION ANIMALS 183
11.3.1.1 Increasing pet ownership and rising focus on pet health and wellness to play key role in driving market growth 183
11.3.2 LIVESTOCK ANIMALS 187
11.3.2.1 Increasing demand for high-quality meat, dairy, and other animal products to aid growth 187
11.3.3 OTHER ANIMALS 191
12 VACCINE ADJUVANTS MARKET, BY REGION 196
12.1 INTRODUCTION 197
12.2 NORTH AMERICA 197
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 198
12.2.2 US 203
12.2.2.1 US to dominate North American market during forecast period 203
12.2.3 CANADA 207
12.2.3.1 Increasing government funding for vaccine research to drive market growth in Canada 207
12.3 EUROPE 211
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 214
12.3.2 GERMANY 215
12.3.2.1 Increasing investments by various key players and growing funding from government organizations to drive market 215
12.3.3 UK 219
12.3.3.1 Rising investments in vaccine development to boost market growth 219
12.3.4 FRANCE 223
12.3.4.1 Focus on new vaccine development to drive market growth 223
12.3.5 ITALY 227
12.3.5.1 Government initiatives for vaccine development to boost market growth 227
12.3.6 SPAIN 231
12.3.6.1 Increasing investments in vaccine development by government and private organizations to support market growth in Spain 231
12.3.7 REST OF EUROPE 234
12.4 ASIA PACIFIC 238
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 243
12.4.2 CHINA 244
12.4.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China 244
12.4.3 JAPAN 248
12.4.3.1 Government initiatives for vaccines to boost market 248
12.4.4 INDIA 252
12.4.4.1 Growth of biotechnology sector and development of new vaccines to support market growth in India 252
12.4.5 SOUTH KOREA 256
12.4.5.1 Strategic collaborations to expand both human and veterinary vaccine sectors in South Korea 256
12.4.6 AUSTRALIA 260
12.4.6.1 Government support and strategic alliances to drive market 260
12.4.7 REST OF ASIA PACIFIC 264
12.5 LATIN AMERICA 267
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 271
12.5.2 BRAZIL 272
12.5.2.1 Robust healthcare infrastructure and thriving livestock industry to support market growth 272
12.5.3 MEXICO 276
12.5.3.1 Government commitment to immunization programs to fuel growth 276
12.5.4 ARGENTINA 279
12.5.4.1 Growing pharmaceutical sector to drive growth in Argentina 279
12.5.5 REST OF LATIN AMERICA 283
12.6 MIDDLE EAST 286
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 286
12.6.2 GCC COUNTRIES 291
12.6.2.1 Saudi Arabia 294
12.6.2.1.1 Strategic emphasis on advancing vaccine development for both human and veterinary applications to fuel growth 294
12.6.2.2 United Arab Emirates (UAE) 298
12.6.2.2.1 Increasing focus on developing cutting-edge vaccine technologies to contribute to market growth 298
12.6.2.3 Rest of GCC countries 302
12.6.3 REST OF MIDDLE EAST 305
12.7 AFRICA 309
12.7.1 INCREASING INVESTMENTS IN VACCINE PRODUCTION FACILITIES TO SUPPORT MARKET GROWTH 309
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 309
13 COMPETITIVE LANDSCAPE 313
13.1 OVERVIEW 313
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023 313
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINE ADJUVANTS MARKET 314
13.3 REVENUE ANALYSIS, 2019–2023 315
13.4 MARKET SHARE ANALYSIS, 2023 316
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 318
13.5.1 STARS 319
13.5.2 EMERGING LEADERS 319
13.5.3 PERVASIVE PLAYERS 319
13.5.4 PARTICIPANTS 319
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 321
13.5.5.1 Company footprint 321
13.5.5.2 Product footprint 322
13.5.5.3 Application footprint 323
13.5.5.4 Region footprint 324
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 325
13.6.1 PROGRESSIVE COMPANIES 325
13.6.2 RESPONSIVE COMPANIES 325
13.6.3 DYNAMIC COMPANIES 325
13.6.4 STARTING BLOCKS 325
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 327
13.7 COMPANY VALUATION & FINANCIAL METRICS 328
13.7.1 FINANCIAL METRICS 328
13.7.2 COMPANY VALUATION 329
13.8 BRAND/PRODUCT COMPARISON 330
13.9 COMPETITIVE SCENARIO 331
13.9.1 PRODUCT LAUNCHES & APPROVALS 331
13.9.2 DEALS 331
13.9.3 EXPANSIONS 332
14 COMPANY PROFILES 333
14.1 KEY PLAYERS 333
14.1.1 GSK PLC 333
14.1.1.1 Business overview 333
14.1.1.2 Products offered 334
14.1.1.3 Recent developments 335
14.1.1.3.1 Deals 335
14.1.1.4 MnM view 335
14.1.1.4.1 Key strengths 335
14.1.1.4.2 Strategic choices 335
14.1.1.4.3 Weaknesses & competitive threats 336
14.1.2 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP) 337
14.1.2.1 Business overview 337
14.1.2.2 Products offered 338
14.1.2.3 Recent developments 339
14.1.2.3.1 Product launches 339
14.1.2.4 MnM view 340
14.1.2.4.1 Key strengths 340
14.1.2.4.2 Strategic choices 340
14.1.2.4.3 Weaknesses & competitive threats 340
14.1.3 CRODA INTERNATIONAL PLC 341
14.1.3.1 Business overview 341
14.1.3.2 Products offered 342
14.1.3.3 Recent developments 344
14.1.3.3.1 Deals 344
14.1.3.3.2 Expansions 345
14.1.3.4 MnM view 345
14.1.3.4.1 Key strengths 345
14.1.3.4.2 Strategic choices 345
14.1.3.4.3 Weaknesses & competitive threats 345
14.1.4 PHIBRO ANIMAL HEALTH CORPORATION 346
14.1.4.1 Business overview 346
14.1.4.2 Products offered 347
14.1.4.3 MnM view 348
14.1.4.3.1 Key strengths 348
14.1.4.3.2 Strategic choices 348
14.1.4.3.3 Weaknesses & competitive threats 348
14.1.5 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC) 349
14.1.5.1 Business overview 349
14.1.5.2 Products offered 351
14.1.5.3 MnM view 352
14.1.5.3.1 Key strengths 352
14.1.5.3.2 Strategic choices 352
14.1.5.3.3 Weaknesses & competitive threats 352
14.1.6 AGENUS INC. 353
14.1.6.1 Business overview 353
14.1.6.2 Products offered 354
14.1.6.3 Recent developments 354
14.1.6.3.1 Deals 354
14.1.7 NOVAVAX 355
14.1.7.1 Business overview 355
14.1.7.2 Products offered 356
14.1.8 AURORIUM (FORMERLY VERTELLUS) 357
14.1.8.1 Business overview 357
14.1.8.2 Products offered 357
14.1.8.3 Recent developments 358
14.1.8.3.1 Deals 358
14.1.9 DYNAVAX TECHNOLOGIES CORPORATION 359
14.1.9.1 Business overview 359
14.1.9.2 Products offered 360
14.1.9.3 Recent developments 361
14.1.9.3.1 Deals 361
14.1.10 MERCK KGAA 362
14.1.10.1 Business overview 362
14.1.10.2 Products offered 363
14.1.11 VAXINE PTY LTD. 364
14.1.11.1 Business overview 364
14.1.11.2 Products offered 364
14.1.12 HAWAII BIOTECH INC. 365
14.1.12.1 Business overview 365
14.1.12.2 Products offered 365
14.1.13 CSL LIMITED 366
14.1.13.1 Business overview 366
14.1.13.2 Products offered 367
14.1.14 OZ BIOSCIENCES 368
14.1.14.1 Business overview 368
14.1.14.2 Products offered 368
14.1.15 INVIVOGEN 370
14.1.15.1 Business overview 370
14.1.15.2 Products offered 371
14.2 OTHER PLAYERS 372
14.2.1 ALLERGY THERAPEUTICS 372
14.2.2 EUBIOLOGICS CO., LTD. 373
14.2.3 PACIFIC GENETECH LIMITED 374
14.2.4 RIBOXX GMBH 375
14.2.5 CAPTIVATE PHARMACEUTICALS LLC 376
14.2.6 CREATIVE DIAGNOSTICS 377
14.2.7 LITEVAX B.V. 378
14.2.8 MUKTA INDUSTRIES 379
14.2.9 ONCOVIR, INC. 380
14.2.10 TITERMAX USA, INC. 381
15 APPENDIX 382
15.1 DISCUSSION GUIDE 382
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 385
15.3 CUSTOMIZATION OPTIONS 387
15.4 RELATED REPORTS 387
15.5 AUTHOR DETAILS 388
LIST OF TABLES
TABLE 1 VACCINE ADJUVANTS MARKET: INCLUSIONS & EXCLUSIONS 36
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 47
TABLE 3 VACCINE ADJUVANTS MARKET: RISK ASSESSMENT ANALYSIS 50
TABLE 4 GLOBAL DIPHTHERIA TETANUS TOXOID AND PERTUSSIS (DTP) VACCINATION COVERAGE, 2019–2023 61
TABLE 5 GLOBAL BACILLUS CALMETTE–GUÉRIN (BCG) VACCINATION COVERAGE,
2019–2023 61
TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 67
TABLE 7 AVERAGE SELLING PRICE OF PRODUCT, BY REGION, 2024 68
TABLE 8 VACCINE ADJUVANTS MARKET: RAW MATERIAL SUPPLIERS 73
TABLE 9 VACCINE ADJUVANTS MARKET: PRODUCT MANUFACTURERS 73
TABLE 10 VACCINE ADJUVANTS MARKET: END USERS 74
TABLE 11 VACCINE ADJUVANTS MARKET: REGULATORY BODIES 74
TABLE 12 KEY PATENTS IN VACCINE ADJUVANTS MARKET 78
TABLE 13 VACCINE ADJUVANTS MARKET: KEY CONFERENCES & EVENTS, 2024–2025 78
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 19 VACCINE ADJUVANTS MARKET: PORTER’S FIVE FORCES ANALYSIS 84
TABLE 20 KEY BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS, BY END USER 87
TABLE 21 IMPORT DATA FOR VACCINE ADJUVANTS 89
TABLE 22 EXPORT DATA FOR VACCINE ADJUVANTS 90
TABLE 23 PIPELINE STUDIES FOR VACCINE ADJUVANTS, PHASE 3 AND PHASE 2|PHASE3 91
TABLE 24 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 95
TABLE 25 EMULSION ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 96
TABLE 26 NORTH AMERICA: EMULSION ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 97
TABLE 27 EUROPE: EMULSION ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 97
TABLE 28 ASIA PACIFIC: EMULSION ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 98
TABLE 29 LATIN AMERICA: EMULSION ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 98
TABLE 30 MIDDLE EAST: EMULSION ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 99
TABLE 31 GCC COUNTRIES: EMULSION ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 99
TABLE 32 PATHOGEN COMPONENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 100
TABLE 33 NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 101
TABLE 34 EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 101
TABLE 35 ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 102
TABLE 36 LATIN AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 102
TABLE 37 MIDDLE EAST: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 103
TABLE 38 GCC COUNTRIES: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 103
TABLE 39 SAPONIN-BASED ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 104
TABLE 40 NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 105
TABLE 41 EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 105
TABLE 42 ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 106
TABLE 43 LATIN AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 106
TABLE 44 MIDDLE EAST: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 107
TABLE 45 GCC COUNTRIES: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 107
TABLE 46 PARTICULATE-BASED ADJUVANTS MARKET, BY REGION,
2022–2029 (USD MILLION) 108
TABLE 47 NORTH AMERICA: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 109
TABLE 48 EUROPE: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 109
TABLE 49 ASIA PACIFIC: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 110
TABLE 50 LATIN AMERICA: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 110
TABLE 51 MIDDLE EAST: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 111
TABLE 52 GCC COUNTRIES: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 111
TABLE 53 OTHER ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 54 NORTH AMERICA: OTHER ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 113
TABLE 55 EUROPE: OTHER ADJUVANTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 56 ASIA PACIFIC: OTHER ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 114
TABLE 57 LATIN AMERICA: OTHER ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 114
TABLE 58 MIDDLE EAST: OTHER ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 115
TABLE 59 GCC COUNTRIES: OTHER ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 115
TABLE 60 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022–2029 (USD MILLION) 117
TABLE 61 ORGANIC VACCINE ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 118
TABLE 62 NORTH AMERICA: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 118
TABLE 63 EUROPE: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 119
TABLE 64 ASIA PACIFIC: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 119
TABLE 65 LATIN AMERICA: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 120
TABLE 66 MIDDLE EAST: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 120
TABLE 67 GCC COUNTRIES: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 121
TABLE 68 INORGANIC VACCINE ADJUVANTS MARKET, BY REGION,
2022–2029 (USD MILLION) 122
TABLE 69 NORTH AMERICA: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 122
TABLE 70 EUROPE: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 123
TABLE 71 ASIA PACIFIC: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 123
TABLE 72 LATIN AMERICA: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 124
TABLE 73 MIDDLE EAST: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 124
TABLE 74 GCC COUNTRIES: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 75 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 127
TABLE 76 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION 128
TABLE 77 VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION,
BY REGION, 2022–2029 (USD MILLION) 128
TABLE 78 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 79 EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 80 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 81 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 82 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 83 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 84 ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION 132
TABLE 85 VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,
BY REGION, 2022–2029 (USD MILLION) 133
TABLE 86 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 87 EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 88 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 89 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 90 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 91 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 92 VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY REGION, 2022–2029 (USD MILLION) 137
TABLE 93 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 94 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 95 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 96 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 97 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 98 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 99 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022–2029 (USD MILLION) 142
TABLE 100 GLOBAL IMMUNIZATION COVERAGE, BY VACCINE, 2020–2023 (%) 143
TABLE 101 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2022–2029 (USD MILLION) 144
TABLE 102 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 103 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 104 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 105 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 106 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 107 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 108 VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION,
2022–2029 (USD MILLION) 148
TABLE 109 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 110 EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY,
2022–2029 (USD MILLION) 149
TABLE 111 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY,
2022–2029 (USD MILLION) 149
TABLE 112 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY,
2022–2029 (USD MILLION) 150
TABLE 113 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY,
2022–2029 (USD MILLION) 150
TABLE 114 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 115 VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION,
2022–2029 (USD MILLION) 152
TABLE 116 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 117 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 118 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 119 LATIN AMERICA: VACCINE ADJUVANTS MARKET OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 120 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 121 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 122 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 157
TABLE 123 VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION,
2022–2029 (USD MILLION) 158
TABLE 124 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 125 EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 126 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 127 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 128 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 129 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 130 VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 162
TABLE 131 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 132 EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 133 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 134 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 135 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 136 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 137 VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022–2029 (USD MILLION) 167
TABLE 138 VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION,
2022–2029 (USD MILLION) 168
TABLE 139 VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY REGION,
2022–2029 (USD MILLION) 168
TABLE 140 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 141 EUROPE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 142 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 143 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 144 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 145 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 146 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 172
TABLE 147 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 148 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 149 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 150 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 151 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 152 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 153 VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 176
TABLE 154 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 155 EUROPE: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 156 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 157 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 158 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 159 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 160 VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 180
TABLE 161 VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY REGION,
2022–2029 (USD MILLION) 180
TABLE 162 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 163 EUROPE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 164 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 165 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 166 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 167 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 168 VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY REGION,
2022–2029 (USD MILLION) 184
TABLE 169 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 170 EUROPE: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 171 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 172 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 173 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 174 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 175 VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY REGION,
2022–2029 (USD MILLION) 188
TABLE 176 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 177 EUROPE: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 178 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 179 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 180 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 181 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 182 VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY REGION,
2022–2029 (USD MILLION) 192
TABLE 183 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 184 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 185 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 186 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 187 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 188 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS,
BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 189 VACCINE ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 197
TABLE 190 NORTH AMERICA: KEY MACROINDICATORS 198
TABLE 191 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 200
TABLE 192 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 200
TABLE 193 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 201
TABLE 194 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 201
TABLE 195 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 201
TABLE 196 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 202
TABLE 197 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 202
TABLE 198 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 202
TABLE 199 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 203
TABLE 200 US: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 204
TABLE 201 US: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 204
TABLE 202 US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 205
TABLE 203 US: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 205
TABLE 204 US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022–2029 (USD MILLION) 205
TABLE 205 US: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022–2029 (USD MILLION) 206
TABLE 206 US: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 206
TABLE 207 US: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 206
TABLE 208 CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 208
TABLE 209 CANADA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 208
TABLE 210 CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 209
TABLE 211 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 209
TABLE 212 CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 209
TABLE 213 CANADA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 210
TABLE 214 CANADA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 210
TABLE 215 CANADA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 210
TABLE 216 EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 217 EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 211
TABLE 218 EUROPE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 212
TABLE 219 EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 212
TABLE 220 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 212
TABLE 221 EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 213
TABLE 222 EUROPE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 213
TABLE 223 EUROPE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 213
TABLE 224 EUROPE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 214
TABLE 225 EUROPE: KEY MACROINDICATORS 215
TABLE 226 GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 216
TABLE 227 GERMANY: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 216
TABLE 228 GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 217
TABLE 229 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 217
TABLE 230 GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 217
TABLE 231 GERMANY: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 218
TABLE 232 GERMANY: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 218
TABLE 233 GERMANY: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 218
TABLE 234 UK: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 220
TABLE 235 UK: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 220
TABLE 236 UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 221
TABLE 237 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 221
TABLE 238 UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022–2029 (USD MILLION) 221
TABLE 239 UK: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022–2029 (USD MILLION) 222
TABLE 240 UK: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 222
TABLE 241 UK: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 222
TABLE 242 FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 224
TABLE 243 FRANCE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 224
TABLE 244 FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 225
TABLE 245 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 225
TABLE 246 FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 225
TABLE 247 FRANCE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 226
TABLE 248 FRANCE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 226
TABLE 249 FRANCE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 226
TABLE 250 ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 228
TABLE 251 ITALY: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 228
TABLE 252 ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 229
TABLE 253 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 229
TABLE 254 ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 229
TABLE 255 ITALY: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 230
TABLE 256 ITALY: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 230
TABLE 257 ITALY: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 230
TABLE 258 SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 231
TABLE 259 SPAIN: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 232
TABLE 260 SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 232
TABLE 261 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 232
TABLE 262 SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 233
TABLE 263 SPAIN: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 233
TABLE 264 SPAIN: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 233
TABLE 265 SPAIN: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 234
TABLE 266 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 235
TABLE 267 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 235
TABLE 268 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 236
TABLE 269 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 236
TABLE 270 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 237
TABLE 271 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 237
TABLE 272 REST OF EUROPE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 237
TABLE 273 REST OF EUROPE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 238
TABLE 274 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 240
TABLE 275 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 240
TABLE 276 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 241
TABLE 277 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 241
TABLE 278 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 241
TABLE 279 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 242
TABLE 280 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 242
TABLE 281 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 242
TABLE 282 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 243
TABLE 283 ASIA PACIFIC: KEY MACROINDICATORS 244
TABLE 284 CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 245
TABLE 285 CHINA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 246
TABLE 286 CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 246
TABLE 287 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 246
TABLE 288 CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 247
TABLE 289 CHINA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 247
TABLE 290 CHINA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 247
TABLE 291 CHINA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 248
TABLE 292 JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 249
TABLE 293 JAPAN: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 249
TABLE 294 JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 250
TABLE 295 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 250
TABLE 296 JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 250
TABLE 297 JAPAN: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 251
TABLE 298 JAPAN: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 251
TABLE 299 JAPAN: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 251
TABLE 300 INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 253
TABLE 301 INDIA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 253
TABLE 302 INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 254
TABLE 303 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 254
TABLE 304 INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 254
TABLE 305 INDIA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 255
TABLE 306 INDIA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 255
TABLE 307 INDIA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 255
TABLE 308 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 257
TABLE 309 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 257
TABLE 310 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 258
TABLE 311 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 258
TABLE 312 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 259
TABLE 313 SOUTH KOREA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 259
TABLE 314 SOUTH KOREA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 259
TABLE 315 SOUTH KOREA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 260
TABLE 316 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 261
TABLE 317 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 261
TABLE 318 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 262
TABLE 319 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 262
TABLE 320 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 262
TABLE 321 AUSTRALIA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 263
TABLE 322 AUSTRALIA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 263
TABLE 323 AUSTRALIA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 263
TABLE 324 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 264
TABLE 325 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 265
TABLE 326 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 265
TABLE 327 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 265
TABLE 328 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 266
TABLE 329 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 266
TABLE 330 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 266
TABLE 331 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 267
TABLE 332 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 268
TABLE 333 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 268
TABLE 334 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 269
TABLE 335 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 269
TABLE 336 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 269
TABLE 337 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 270
TABLE 338 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 270
TABLE 339 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 270
TABLE 340 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 271
TABLE 341 LATIN AMERICA: KEY MACROINDICATORS 272
TABLE 342 BRAZIL: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 273
TABLE 343 BRAZIL: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 273
TABLE 344 BRAZIL: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 274
TABLE 345 BRAZIL: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 274
TABLE 346 BRAZIL: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 274
TABLE 347 BRAZIL: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 275
TABLE 348 BRAZIL: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 275
TABLE 349 BRAZIL: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 275
TABLE 350 MEXICO: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 276
TABLE 351 MEXICO: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 277
TABLE 352 MEXICO: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 277
TABLE 353 MEXICO: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 277
TABLE 354 MEXICO: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 278
TABLE 355 MEXICO: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 278
TABLE 356 MEXICO: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 278
TABLE 357 MEXICO: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 279
TABLE 358 ARGENTINA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 280
TABLE 359 ARGENTINA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 280
TABLE 360 ARGENTINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 281
TABLE 361 ARGENTINA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 281
TABLE 362 ARGENTINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 281
TABLE 363 ARGENTINA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 282
TABLE 364 ARGENTINA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 282
TABLE 365 ARGENTINA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 282
TABLE 366 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 283
TABLE 367 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022–2029 (USD MILLION) 284
TABLE 368 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 284
TABLE 369 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 284
TABLE 370 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 285
TABLE 371 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 285
TABLE 372 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 285
TABLE 373 REST OF LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 286
TABLE 374 MIDDLE EAST: KEY MACROINDICATORS 287
TABLE 375 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 287
TABLE 376 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 288
TABLE 377 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 288
TABLE 378 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 289
TABLE 379 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 289
TABLE 380 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 289
TABLE 381 MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 290
TABLE 382 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 290
TABLE 383 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 290
TABLE 384 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 291
TABLE 385 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 291
TABLE 386 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 292
TABLE 387 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 292
TABLE 388 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 292
TABLE 389 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 293
TABLE 390 GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 293
TABLE 391 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 293
TABLE 392 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 294
TABLE 393 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 295
TABLE 394 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 295
TABLE 395 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 296
TABLE 396 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 296
TABLE 397 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 296
TABLE 398 SAUDI ARABIA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 297
TABLE 399 SAUDI ARABIA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 297
TABLE 400 SAUDI ARABIA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 297
TABLE 401 UAE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 299
TABLE 402 UAE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 299
TABLE 403 UAE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 300
TABLE 404 UAE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 300
TABLE 405 UAE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 300
TABLE 406 UAE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 301
TABLE 407 UAE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 301
TABLE 408 UAE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 301
TABLE 409 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 302
TABLE 410 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022–2029 (USD MILLION) 303
TABLE 411 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 303
TABLE 412 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 303
TABLE 413 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022–2029 (USD MILLION) 304
TABLE 414 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022–2029 (USD MILLION) 304
TABLE 415 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 304
TABLE 416 REST OF GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 305
TABLE 417 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 306
TABLE 418 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 306
TABLE 419 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 307
TABLE 420 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 307
TABLE 421 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 307
TABLE 422 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 308
TABLE 423 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES,
BY APPLICATION, 2022–2029 (USD MILLION) 308
TABLE 424 REST OF MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 308
TABLE 425 AFRICA: KEY MACROINDICATORS 310
TABLE 426 AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 310
TABLE 427 AFRICA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE,
2022–2029 (USD MILLION) 310
TABLE 428 AFRICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 311
TABLE 429 AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 311
TABLE 430 AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022–2029 (USD MILLION) 311
TABLE 431 AFRICA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE,
2022–2029 (USD MILLION) 312
TABLE 432 AFRICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 312
TABLE 433 AFRICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 312
TABLE 434 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINE ADJUVANTS MARKET 314
TABLE 435 VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION 317
TABLE 436 VACCINE ADJUVANTS MARKET: PRODUCT FOOTPRINT 322
TABLE 437 VACCINE ADJUVANTS MARKET: APPLICATION FOOTPRINT 323
TABLE 438 VACCINE ADJUVANTS MARKET: REGION FOOTPRINT 324
TABLE 439 VACCINE ADJUVANTS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 327
TABLE 440 VACCINE ADJUVANTS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 328
TABLE 441 VACCINE ADJUVANTS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–OCTOBER 2024 331
TABLE 442 VACCINE ADJUVANTS MARKET: DEALS, JANUARY 2021–OCTOBER 2024 331
TABLE 443 VACCINE ADJUVANTS MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024 332
TABLE 444 GSK PLC: COMPANY OVERVIEW 333
TABLE 445 GSK PLC: PRODUCTS OFFERED 334
TABLE 446 GSK PLC: DEALS, JANUARY 2021–OCTOBER 2024 335
TABLE 447 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): COMPANY OVERVIEW 337
TABLE 448 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): PRODUCTS OFFERED 338
TABLE 449 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): PRODUCT LAUNCHES,
JANUARY 2021–OCTOBER 2024 339
TABLE 450 CRODA INTERNATIONAL PLC: COMPANY OVERVIEW 341
TABLE 451 CRODA INTERNATIONAL PLC: PRODUCTS OFFERED 342
TABLE 452 CRODA INTERNATIONAL PLC: DEALS, JANUARY 2021–OCTOBER 2024 344
TABLE 453 CRODA INTERNATIONAL PLC: EXPANSIONS, JANUARY 2021–OCTOBER 2024 345
TABLE 454 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY OVERVIEW 346
TABLE 455 PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED 347
TABLE 456 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC):
COMPANY OVERVIEW 349
TABLE 457 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC):
PRODUCTS OFFERED 351
TABLE 458 AGENUS INC.: COMPANY OVERVIEW 353
TABLE 459 AGENUS INC.: PRODUCTS OFFERED 354
TABLE 460 AGENUS INC.: DEALS, JANUARY 2021–OCTOBER 2024 354
TABLE 461 NOVAVAX: COMPANY OVERVIEW 355
TABLE 462 NOVAVAX: PRODUCTS OFFERED 356
TABLE 463 AURORIUM (FORMERLY VERTELLUS): COMPANY OVERVIEW 357
TABLE 464 AURORIUM (FORMERLY VERTELLUS): PRODUCTS OFFERED 357
TABLE 465 AURORIUM (FORMERLY VERTELLUS): DEALS, JANUARY 2021–OCTOBER 2024 358
TABLE 466 DYNAVAX TECHNOLOGIES CORPORATION: COMPANY OVERVIEW 359
TABLE 467 DYNAVAX TECHNOLOGIES CORPORATION: PRODUCTS OFFERED 360
TABLE 468 DYNAVAX TECHNOLOGIES CORPORATION: DEALS,
JANUARY 2021−NOVEMBER 2024 361
TABLE 469 MERCK KGAA: COMPANY OVERVIEW 362
TABLE 470 MERK KGAA: PRODUCTS OFFERED 363
TABLE 471 VAXINE PTY LTD.: COMPANY OVERVIEW 364
TABLE 472 VAXINE PTY LTD.: PRODUCTS OFFERED 364
TABLE 473 HAWAII BIOTECH INC.: COMPANY OVERVIEW 365
TABLE 474 HAWAII BIOTECH INC.: PRODUCTS OFFERED 365
TABLE 475 CSL LIMITED: COMPANY OVERVIEW 366
TABLE 476 CSL LIMITED: PRODUCTS OFFERED 367
TABLE 477 OZ BIOSCIENCES: COMPANY OVERVIEW 368
TABLE 478 OZ BIOSCIENCES: PRODUCTS OFFERED 368
TABLE 479 INVIVOGEN: COMPANY OVERVIEW 370
TABLE 480 INVIVOGEN: PRODUCTS OFFERED 371
TABLE 481 ALLERGY THERAPEUTICS: COMPANY OVERVIEW 372
TABLE 482 EUBIOLOGICS CO., LTD.: COMPANY OVERVIEW 373
TABLE 483 PACIFIC GENETECH LIMITED: COMPANY OVERVIEW 374
TABLE 484 RIBOXX GMBH: COMPANY OVERVIEW 375
TABLE 485 CAPTIVATE PHARMACEUTICALS LLC: COMPANY OVERVIEW 376
TABLE 486 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 377
TABLE 487 LITEVAX B.V.: COMPANY OVERVIEW 378
TABLE 488 MUKTA INDUSTRIES: COMPANY OVERVIEW 379
TABLE 489 ONCOVIR, INC.: COMPANY OVERVIEW 380
TABLE 490 TITERMAX USA, INC.: COMPANY OVERVIEW 381
LIST OF FIGURES
FIGURE 1 VACCINE ADJUVANTS MARKET SEGMENTATION & REGIONAL SCOPE 35
FIGURE 2 RESEARCH DESIGN 39
FIGURE 3 VACCINE ADJUVANTS MARKET: BREAKDOWN OF PRIMARIES 41
FIGURE 4 VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 42
FIGURE 5 GLOBAL MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 43
FIGURE 6 ILLUSTRATIVE EXAMPLE OF GSK PLC: REVENUE SHARE ANALYSIS (2023) 43
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 44
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 44
FIGURE 9 VACCINE ADJUVANTS MARKET: CAGR PROJECTIONS 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 48
FIGURE 11 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 51
FIGURE 12 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2024 VS. 2029 (USD MILLION) 52
FIGURE 13 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 53
FIGURE 14 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2024 VS. 2029 (USD MILLION) 54
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET 55
FIGURE 16 ADVANCEMENTS IN VACCINE ADJUVANTS AND RISING DEMAND FOR BIO-BASED PRODUCTS TO DRIVE MARKET GROWTH 56
FIGURE 17 ADJUVANT EMULSIONS SEGMENT ACCOUNTED FOR LARGEST
MARKET SHARE IN 2023 57
FIGURE 18 HUMAN VACCINES TO DOMINATE MARKET DURING FORECAST PERIOD 58
FIGURE 19 CHINA PROJECTED TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 59
FIGURE 20 VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN VACCINE ADJUVANTS MARKET 66
FIGURE 22 VACCINE ADJUVANTS MARKET: SUPPLY CHAIN ANALYSIS 69
FIGURE 23 VACCINE ADJUVANTS MARKET: VALUE CHAIN ANALYSIS 71
FIGURE 24 VACCINE ADJUVANTS MARKET: ECOSYSTEM ANALYSIS 72
FIGURE 25 NUMBER OF PATENTS APPLICATIONS/GRANTED, 2014−2024 77
FIGURE 26 VACCINE ADJUVANTS MARKET: PORTER’S FIVE FORCES ANALYSIS 84
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINE ADJUVANT PRODUCTS 86
FIGURE 28 KEY BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS AMONG END USERS 87
FIGURE 29 VACCINE ADJUVANTS PIPELINE, BY PHASE 91
FIGURE 30 VACCINE ADJUVANTS MARKET: IMPACT OF AI 93
FIGURE 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT 199
FIGURE 32 ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT 239
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET,
2019–2023 315
FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET (2023) 317
FIGURE 35 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 320
FIGURE 36 VACCINE ADJUVANTS MARKET: COMPANY FOOTPRINT 321
FIGURE 37 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 326
FIGURE 38 EV/EBITDA OF KEY VENDORS 328
FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 329
FIGURE 40 VACCINE ADJUVANTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 330
FIGURE 41 GSK PLC: COMPANY SNAPSHOT (2023) 334
FIGURE 42 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): COMPANY SNAPSHOT (2023) 338
FIGURE 43 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2023) 342
FIGURE 44 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2023) 347
FIGURE 45 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC):
COMPANY SNAPSHOT (2023) 350
FIGURE 46 AGENUS INC.: COMPANY SNAPSHOT (2023) 353
FIGURE 47 NOVAVAX: COMPANY SNAPSHOT (2023) 355
FIGURE 48 DYNAVAX TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT (2023) 360
FIGURE 49 MERCK KGAA: COMPANY SNAPSHOT (2023) 363
FIGURE 50 CSL LIMITED: COMPANY SNAPSHOT (2023) 367
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11